WELLESLEY HILLS, Mass., Oct. 12, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale.
Some companies with S1P modulators in development currently are: Novartis, Actelion, Lexicon, Pfizer, Ono Pharmaceuticals, Glaxo Smith Kline, Mitsubishi Tanabe Pharma, Receptos, Arena Pharmaceuticals, Exelixis, Boehringer Ingelheim, Biogen Idec, Kyorin, Angio, Apogee Biotechnology and Lpath.
Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – email@example.com or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in loan workouts and bankruptcy cases for 37 years. His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or firstname.lastname@example.org<
|SOURCE Joseph F. Finn, Jr., C.P.A.|
Copyright©2010 PR Newswire.
All rights reserved